Adamas Pharma (ADMS) Announces Submission of ADS-5102 NDA to U.S. FDA as Dyskinesia Treatment in PD Patients
Get inside Wall Street with StreetInsider Premium. Claim your 2-week free trial here.
Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS) announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ADS-5102 (amantadine hydrochloride) extended-release capsules, the company’s proprietary lead product candidate, for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). In April 2015, the FDA granted orphan drug status to ADS-5102 for this indication.
“The ADS-5102 NDA submission represents a major milestone both for Adamas and for patients with Parkinson’s disease who are challenged to complete the tasks of everyday life as a result of LID,” said Gregory T. Went, Ph.D., Chairman and Chief Executive Officer of Adamas Pharmaceuticals, Inc. “If approved, ADS-5102 would represent a new approach to treating LID and would be the first drug approved in the United States for this condition. We thank the physicians, patients and caregivers involved in our clinical trials for their pioneering spirit and support in helping us reach this critical milestone.”
The ADS-5102 NDA is supported by efficacy and safety data compiled from Adamas’ comprehensive registration program, which was designed to evaluate ADS-5102 for the treatment of LID in patients with PD. The clinical program included three placebo-controlled trials: EASED, EASE LID and EASE LID 3. The three trials enrolled a total of 286 patients, of whom 121 patients received a 340 mg dose of ADS-5102 once daily at bedtime. Both Phase 3 trials met their primary and key secondary endpoints.
In addition, the NDA is supported by data from an open-label safety study known as EASE LID 2 for patients from EASED, EASE LID and EASE LID 3 as well as LID patients who have undergone deep brain stimulation. The EASE LID 2 trial is ongoing, and patients are being followed for up to two years.
ADS-5102 is a chrono-synchronous amantadine therapy for the potential treatment of levodopa-induced dyskinesia (LID) in patients with Parkinson’s disease (PD). ADS-5102 is dosed once daily at bedtime to time the delivery of drug levels of amantadine to waking hours when LID episodes are most frequent and movement control is needed most. With bedtime dosing, the amantadine plasma concentrations rise slowly during the night to avoid sleep disturbance, with peak and plateau achieved from early morning to mid-day, declining in the late afternoon and evening. We are also investigating ADS-5102 for the treatment of walking impairment in multiple sclerosis (MS) patients, and we plan to pursue a pivotal registration program for this indication.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Cascadian Therapeutics (CASC) Amends Tucatinib HER2CLIMB Phase 2; Increases Sample Size
- Xerox Corp. (XRX) Updates on Growth Expectations, Initiatives Post-Conduent (CNDT) Spin-off
- Cellceutix Corporation (CTIX) Commences Second Cohort of Brilacidin Phase 2 in IBD
Create E-mail Alert Related CategoriesCorporate News, FDA, Management Comments
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!